Risk assessment for recurrent venous thrombosis – The Lancet (as it applies to transdermal oestrogens)

Note:  author's response to commentaries on the original research article,  links  included to the discussion

Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen - abstr

Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study

Conclusions The use of transdermal HRT containing low doses of oestrogen does not seem to increase the risk of stroke. The presence of residual confounding, however, cannot be entirely excluded in the interpretation of this finding.

(financial news source) Non-Patch, Transdermal Estrogen Products Such as Divigel(R) Are Effective Hormone Therapy Alternatives to Oral Estrogen